2025-06-05-Jefferies-维罗纳（VRNA）_炉边谈话_Ohtuvayre在慢性阻塞性肺疾病（COPD）领域崛起_2025年仍未察觉到放缓_8页_248kb

Verona Pharma (VRNA) Equity Research Summary

Ohtuvayre for COPD

Ohtuvare is a novel PDE3/4 inhibitor for uncontrolled chronic obstructive pulmonary disease (COPD), viewed as an attractive add-on therapy with potential to generate +$2.5B annually. It boasts a strong MOA that can be stacked with all existing therapies, competitive efficacy, placebo-like safety, and improved dyspnea.

Financial & Rating

The report recommends a "Buy" rating with a price target of $95 (+13% upside), up from prior targets. Current price is $83.98 with a 52-week range of $86.59–$11.79. Analysts believe 2025 consensus sales of $91M (up from $404M) and first-quarter 2025 figures of $71M are beatable, surpassing other COPD drugs.

Key Growth Drivers

• Strong consumer uptake: Every 1% market share could bring over $1B in revenue.
• Market penetration: Initial share projections show room for growth, with less than half of the U.S. COPD patient market addressed by July 2025.
• Sales trajectory: Positive feedback from physicians and patients empowers wider prescribing. Refill adherence is strong (60% of prescriptions in Q1:25), aiding persistence.
• Expansion: Ohtuvayre launch setup is "incredibly strong," with no regulatory or payor bottlenecks.

Outlook 2025–26

• No Q2:25 slowdown expected; management aims for accelerated growth, partly through 30 new sales representatives.
• Potential for peak sales of $3–5B, driving a ~$13B valuation at a 3x multiple.
• Pipeline explores expanded use into NCFBE and other indications, with Phase IIb data anticipated by late 2026.

Risks & Valuation

• Risks: Single-product focus, clinical/regulatory uncertainty, competition, and delayed profitability.
• Value drivers: Revenue run rate assumptions of $250M–$300M support positive cash flow and future pipeline investments.

Analyst Note

All recommendations are from Jefferies coverage with price targets based on DCF and growth analyses. Jefferies highlights Ohtuvayre as a market-changing asset with upside in physician/channel prioritization.